Actin vs myRocky
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
myRocky
Best for US patients in the 42 supported states who specifically want brand-name FDA-approved GLP-1 receptor agonists without insurance involvement AND are also managing additional conditions covered by myRocky's multi-product platform (sexual health, hair loss, mental health) so the $99/mo program fee amortizes across multiple medications. NOT recommended for patients sensitive to total monthly cost — compounded providers ($99-$199/mo) and direct manufacturer programs (NovoCare, LillyDirect) offer better economics.Starting at $1409/mo
Side-by-Side Comparison
| Feature | Actin | myRocky |
|---|---|---|
| Overall Score | ✓7.0/10 | 6.1/10 |
| Starting Price | ✓$133/mo | $1409/mo |
| Editorial Rating | ✓3.5 ★ /5 | 3.1 ★ /5 |
| Features | 2 features | ✓8 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
myRocky
Pros
- ✓Brand-name FDA-approved GLP-1 receptor agonists (Ozempic, Mounjaro, Wegovy) on a single platform — no compounded-product YMYL risk
- ✓LegitScript Approved (#44796030)
- ✓42-state US coverage with 8-state Phase 2 expansion roadmap published
- ✓Multi-product platform appeals to patients managing multiple conditions (GLP-1 + sexual health + hair loss + mental health) on one subscription
Cons
- ✗Stacked-fee structure is expensive: $99 consultation + $99/mo program fee + $1,409/mo medication = ~$1,508/mo first month, ~$1,508/mo ongoing — well above typical compounded providers ($99-$199/mo all-in) and above LillyDirect Self Pay Journey Program ($449-$699/mo Zepbound vials)
- ✗Canadian incorporation (Rocky Health Inc., Mississauga, ON L4W 5M8) with US-state prescriber operationalization opaque — patients should verify their state's prescriber holds an active US license before enrolling
- ✗Listed pharmacy (Rocky Pharmacy #308582, Mississauga ON) is a Canadian community pharmacy — US-fulfillment supply chain not transparent on public-facing pages
- ✗Multi-product platform may indicate prescriber bandwidth is split across many conditions (less GLP-1-specific expertise vs single-product specialists)
- ✗Brand-only (no compounded option) limits cost-sensitive patient access
- ✗$1,409/mo Ozempic pricing is near-retail; insured patients should pursue PA through traditional pharmacy for better economics — uninsured patients should compare NovoCare ($349/mo Wegovy pen ongoing) or LillyDirect Self Pay ($449-$699/mo Zepbound vials)
Our Verdict
Actin edges out myRocky with a higher overall score of 7.0/10 and is particularly strong for affordable compounded semaglutide with B12 enhancement. myRocky remains a solid alternative, especially if you're looking for US patients in the 42 supported states who specifically want brand-name FDA-approved GLP-1 receptor agonists without insurance involvement AND are also managing additional conditions covered by myRocky's multi-product platform (sexual health, hair loss, mental health) so the $99/mo program fee amortizes across multiple medications. NOT recommended for patients sensitive to total monthly cost — compounded providers ($99-$199/mo) and direct manufacturer programs (NovoCare, LillyDirect) offer better economics..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.